




Instance: composition-en-6b7b5522c872887b5587c6d7e9f380f6
InstanceOf: CompositionUvEpi
Title: "Composition for onureg Package Leaflet"
Description:  "Composition for onureg Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6b7b5522c872887b5587c6d7e9f380f6)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - onureg"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #en
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What is in this leaflet</p>
<ol>
<li>What Onureg is and what it is used for </li>
<li>What you need to know before you take Onureg </li>
<li>How to take Onureg </li>
<li>Possible side effects </li>
<li>How to store Onureg </li>
<li>Contents of the pack and other information </li>
</ol>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What onureg is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What onureg is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Onureg is 
Onureg is an anti-cancer medicine that belongs to a group of medicines called anti-metabolites. 
Onureg contains the active substance azacitidine. </p>
<p>What Onureg is used for<br />
Onureg is used to treat adults with acute myeloid leukaemia (AML). This is a form of cancer which 
affects your bone marrow and can cause problems with producing normal blood cells. </p>
<p>Onureg is used to keep the disease in control (remission, when the disease is less severe or not active). </p>
<p>How Onureg works 
Onureg works by preventing cancer cells from growing. Azacitidine, the active substance in Onureg, 
works by altering the way the cell turns genes on and off. It also reduces the production of new genetic 
material (RNA and DNA). These effects are thought to block growth of cancer cells in leukaemia. </p>
<p>Talk to your doctor or nurse if you have any questions about how Onureg works or why this medicine 
has been prescribed for you. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take onureg"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take onureg"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Do not take Onureg 
  if you are allergic to azacitidine or any of the other ingredients of this medicine (listed in section 6). 
  if you are breast-feeding. </p>
<p>Warnings and precautions </p>
<p>Blood tests 
You will have blood tests before you begin treatment with Onureg and during treatment with Onureg 
to check that you have enough blood cells and that your liver and kidneys are working properly. Your 
doctor will decide how often you have blood tests. </p>
<p>Tell your doctor, pharmacist or nurse straight away if you get any of these symptoms during treatment 
with Onureg: 
  bruising or bleeding - this could be due to a low count of blood cells called platelets; 
  fever - this could be due to an infection as a result of having low levels of white blood cells, which 
can be life-threatening; 
  diarrhoea, vomiting or nausea (feeling sick). </p>
<p>Your doctor may need to change the dose, interrupt treatment or stop treatment with Onureg 
completely. The doctor may prescribe other medicines to help manage these symptoms. </p>
<p>Children and adolescents 
Onureg is not recommended for use in children and adolescents below the age of 18. Other medicines and Onureg<br />
Tell your doctor if you are taking, have recently taken or might take any other medicines. This is 
because Onureg may affect the way some other medicines work. Also, some other medicines may 
affect the way Onureg works. </p>
<p>Pregnancy, contraception and breast-feeding 
If you are pregnant or breast-feeding, you think you may be pregnant or are planning to have a baby, 
ask your doctor for advice before taking this medicine. Men should not father a child while receiving 
treatment with Onureg. </p>
<p>Pregnancy 
Do not take Onureg during pregnancy as it may be harmful to your baby. Tell your doctor straight 
away if you become pregnant during treatment. </p>
<p>Contraception 
If you are a woman who can become pregnant you should use an effective method of contraception 
while taking Onureg and for 6 months after stopping treatment with Onureg. Men should use an 
effective method of contraception while taking Onureg and for 3 months after stopping treatment with 
Onureg.  </p>
<p>Your doctor will discuss with you the most suitable method of contraception for you to use. </p>
<p>Breast-feeding 
Do not breast-feed while taking Onureg as it may be harmful to your child. </p>
<p>Fertility 
Onureg may affect your ability to have a baby. Talk to your doctor for advice before using it. </p>
<p>Driving and using machines or tools 
You may feel tired, weak or have trouble concentrating. If this happens to you or if you have other 
side effects, do not drive or use any machines or tools. </p>
<p>Onureg contains lactose 
Onureg contains lactose. If you have been told by your doctor that you have intolerance to some 
sugars, contact your doctor before taking this medicine. </p>
<p>Onureg contains sodium 
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially 
 sodium-free . </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take onureg"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take onureg"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not 
sure. </p>
<p>How much to take 
  The recommended dose is 300 mg taken by mouth once daily. 
  Your doctor may reduce your dose to 200 mg once daily. </p>
<p>Onureg is given in treatment cycles of 28 days. 
  You take Onureg every day for the first 14 days of each 28-day cycle. 
  This is followed by a treatment-free period of 14 days for the rest of the cycle. </p>
<p>Your doctor will tell you what dose of Onureg to take. The doctor may decide to: 
  extend your treatment beyond 14 days in each treatment cycle 
  lower your dose or temporarily stop treatment 
  reduce your treatment to 7 days. 
Always take Onureg as prescribed by your doctor. </p>
<p>Your doctor will give you a medicine that helps to reduce nausea (feeling sick)  and vomiting. You 
take it 30 minutes before each Onureg tablet, during your first and second treatment cycles. Your 
doctor will tell you to take it for a longer period, if you need it. </p>
<p>Taking this medicine 
  Take Onureg once a day - at the same time each day. 
  Swallow the tablets whole with a full glass of water. 
  To make sure you get the right dose, do not break, crush, dissolve or chew the tablets. 
  You can take the medicine with food or between meals. 
If you vomit after taking a tablet, do not take another dose on the same day. Instead, wait till the next 
day and take your next scheduled dose then. Do not take two doses on the same day. </p>
<p>If powder from a broken tablet touches your skin, wash the skin straight away and thoroughly with 
soap and water. If the powder gets into your eyes, nose or mouth, flush the area thoroughly with water. </p>
<p>If you take more Onureg than you should 
If you take more tablets than you should, contact your doctor or go to a hospital straightaway. If 
possible, take the medicine pack and this leaflet with you. </p>
<p>If you forget to take Onureg 
If you forget to take Onureg at the usual time, take your usual dose as soon as you remember on the 
same day and take your next dose at the usual time the next day. Do not take a double dose to make up 
for a forgotten or vomited tablet. </p>
<p>If you stop taking Onureg 
Do not stop taking Onureg unless your doctor tells you to. </p>
<p>If you have any further questions on the use of this medicine, ask your doctor. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. </p>
<p>Serious side effects 
Tell your doctor, pharmacist or nurse straight away if you get any of these symptoms during 
treatment with Onureg: 
  bruising or bleeding - this could be due to a low count of blood cells called platelets; 
  fever - this could be due to an infection as a result of having low levels of white blood cells, which 
can be life-threatening; 
  diarrhoea, vomiting or nausea (feeling sick). </p>
<p>Other side effects include: </p>
<p>Very common side effects (may affect more than 1 in 10 people): 
  constipation 
  pain in your belly 
  infections of the nose, sinuses and throat 
  infection of the lungs 
  feeling tired or weak 
  loss of appetite 
  pain that affect different parts of the body - this can range from a sharp pain to a dull ache 
  stiff joints 
  back pain. </p>
<p>Common side effects  (may affect up to 1 in 10 people): 
  flu 
  infection of the urinary tract 
  hay fever 
  anxiety 
  loss of weight. </p>
<p>Reporting of side effects 
If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this 
leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. 
By reporting side affects you can help provide more information on the safety of this medicine. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store onureg"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store onureg"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Keep this medicine out of the sight and reach of children. </p>
<p>Do not use this medicine after the expiry date which is stated on the blister and the carton after EXP. 
The expiry date refers to the last day of that month. </p>
<p>This medicine does not require any special storage conditions. </p>
<p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to 
throw away medicines you no longer use. These measures will help protect the environment. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>What Onureg contains 
  The active substance is azacitidine. Each film-coated tablet contains either 200 mg or 300 mg 
azacitidine. 
  The other ingredients are croscarmellose sodium (E468), magnesium stearate (E572), mannitol 
(E421), and silicified microcrystalline cellulose (E460, E551).  </p>
<p>The 200 mg tablet coating   Opadry II pink contains: hypromellose (E464), titanium dioxide 
(E171), lactose monohydrate, polyethylene glycol/macrogols (E1521), triacetin (E1518), and iron 
oxide red (E172). See section 2  Onureg contains sodium . </p>
<p>The 300 mg tablet coating   Opadry II brown contains: hypromellose (E464), titanium dioxide 
(E171), lactose monohydrate, polyethylene glycol/macrogols (E1521), triacetin (E1518), iron oxide 
red (E172), iron oxide yellow (E172), and iron oxide black (E172). See section 2  Onureg contains 
sodium . </p>
<p>What Onureg looks like and contents of the pack </p>
<p>Onureg 200 mg film-coated tablets are pink and oval shaped with  200  imprinted on one side and 
 ONU  on the other side. </p>
<p>Onureg 300 mg film-coated tablets are brown and oval shaped with  300  imprinted on one side and 
 ONU  on the other side. </p>
<p>The film-coated tablets are packaged in aluminium foil blisters. </p>
<p>Each pack contains either 7 or 14 film-coated tablets. Not all pack sizes may be marketed. </p>
<p>Marketing Authorisation Holder<br />
Bristol-Myers Squibb Pharma EEIG 
Plaza Blanchardstown Corporate Park 2 
Dublin 15, D15 TIreland </p>
<p>Manufacturer 
Celgene Distribution B.V.<br />
Orteliuslaan 13528 BD Utrecht<br />
Netherlands </p>
<p>This leaflet was last revised in </p>
<p>Other sources of information </p>
<p>Detailed information on this medicine is available on the European Medicines Agency web site: </p>         </div>"""      



Instance: composition-da-6b7b5522c872887b5587c6d7e9f380f6
InstanceOf: CompositionUvEpi
Title: "Composition for onureg Package Leaflet"
Description:  "Composition for onureg Package Leaflet"
Usage: #inline

* identifier.system = "http://ema.europa.eu/identifier"

* identifier.value = "identifier"
* status = #final

* type = https://spor.ema.europa.eu/rmswi/#100000155538
* type.text = "Package Leaflet"

* subject = Reference(mp6b7b5522c872887b5587c6d7e9f380f6)
* date = "2022-02-16T13:28:17Z"

 

 // Reference to Organization: MAH
* author = Reference(mah-ema)


* title = "TEST PURPOSES ONLY - onureg"
* attester.mode = http://hl7.org/fhir/composition-attestation-mode#official
* attester.time =  "2022-02-16T13:28:17Z"
* language = #da
* category = epicategory-cs#R "Raw"


* section[+].
  * title = "B. Package Leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "B. Package Leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   


      
* section[=].section[+]
  * title = "Package leaflet: Information for the user"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "Package leaflet: Information for the user"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>           </div>"""   



* section[=].section[+]
  * title = "What is in this leaflet"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "What is in this leaflet"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Oversigt over indlægssedlen 
1. Virkning og anvendelse<br />
2. Det skal du vide, før du begynder at tage Onureg 
3. Sådan skal du tage Onureg 
4. Bivirkninger 
5. Opbevaring 
6. Pakningsstørrelser og yderligere oplysninger </p>         </div>"""   
          

* section[=].section[+]
  * title =  "1. What onureg is and what it is used for"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text =  "1. What onureg is and what it is used for"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Virkning 
Onureg er et lægemiddel mod kræft, der tilhører en gruppe lægemidler, der kaldes ’antimetabolitter’.<br />
Onureg indeholder det aktive stof ’azacitidin’. </p>
<p>Anvendelse 
Onureg anvendes til voksne med akut myeloid leukæmi (AML). Det er en form for kræft, der påvirker 
knoglemarven - og som kan forårsage problemer med den normale produktion af blodlegemer. </p>
<p>Onureg anvendes til at holde sygdommen i kontrol (remission, hvor sygdommen er mindre alvorlig 
eller ikke aktiv). </p>
<p>Sådan virker Onureg 
Onureg virker ved at forhindre kræftcellernes vækst. Azacitidin, den aktive ingrediens i Onureg, virker 
ved at ændre den måde, cellerne tænder og slukker for generne på, samt ved at påvirke produktionen 
af nyt genetisk materiale (RNA og DNA). Disse virkninger menes at blokere kræftcellernes vækst ved 
leukæmi. </p>
<p>Kontakt lægen eller sygeplejersken, hvis du har spørgsmål om Onuregs virkning eller hvorfor du har 
fået ordineret dette lægemiddel. </p>         </div>"""   
          

             
* section[=].section[+]
  * title = "2. What you need to know before you take onureg"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "2. What you need to know before you take onureg"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag ikke Onureg </p>
<ul>
<li>hvis du er allergisk over for azacitidin eller et af de øvrige indholdsstoffer i dette lægemiddel 
angivet i afsnit 6. * hvis du ammer. </li>
</ul>
<p>Advarsler og forsigtighedsregler </p>
<p>Blodprøver 
Du vil få taget blodprøver, inden du påbegynder behandlingen med Onureg - og under behandlingen 
med Onureg for at kontrollere, at du har nok blodlegemer, og at din lever og dine nyrer fungerer 
korrekt. Din læge vil vurdere hvor ofte du skal have taget blodprøver. </p>
<p>Kontakt straks lægen, apotekspersonalet eller sygeplejersken, hvis du får nogle af disse symptomer 
under behandlingen med Onureg: </p>
<ul>
<li>
<p>blå mærker eller blødning - dette kan skyldes et lavt antal blodlegemer kaldet "blodplader". </p>
</li>
<li>
<p>feber - dette kan skyldes en infektion, som følge af at have et lavt niveau af hvide 
blodlegemer, hvilket kan være livstruende. </p>
</li>
<li>
<p>diarré, opkastning eller kvalme (føler dig syg). </p>
</li>
</ul>
<p>Det kan være nødvendigt for din læge at ændre i doseringen, afbryde behandlingen eller stoppe 
behandlingen med Onureg fuldstændigt. Din læge kan udskrive andre lægemidler, som hjælper på 
disse symptomer. </p>
<p>Børn og unge<br />
Onureg bør ikke anvendes til børn og unge under 18 år. </p>
<p>Brug af anden medicin sammen med Onureg 
Fortæl altid lægen, hvis du tager anden medicin, for nylig har taget anden medicin eller planlægger at 
tage anden medicin. Dette er fordi, at Onureg kan påvirke måde som anden medicin virker på. Anden 
medicin kan også påvirke måden som Onureg virker på. </p>
<p>Graviditet, prævention og amning 
Hvis du er gravid eller ammer, har mistanke om, at du er gravid, eller planlægger at blive gravid, skal 
du spørge din læge til råds, før du tager dette lægemiddel. Mænd bør ikke blive far under behandling 
med Onureg. </p>
<p>Graviditet 
Du må ikke tage Onureg under graviditet, da det kan være skadeligt for fosteret. Fortæl det straks til 
din læge, hvis du bliver gravid under behandlingen. </p>
<p>Prævention 
Hvis du er kvinde, som kan blive gravid, skal du bruge en sikker præventionsmetode under behandling 
med Onureg og  i op til 6 måneder efter behandlingen med Onureg er stoppet. Mænd skal bruge en 
sikker præventionsmetode under behandling med Onureg og i op til 3 måneder efter behandlingen med 
Onureg er stoppet. </p>
<p>Din læge vil snakke med dig om den bedst egnede præventionsmetode for dig at bruge. </p>
<p>Amning 
Du må ikke amme, mens du tager Onureg, da det kan skade dit barn. </p>
<p>Frugtbarhed 
Onureg kan påvirke din evne til at få børn. Tal med din læge om det, før du tager det. </p>
<p>Trafik- og arbejdssikkerhed 
Du kan føle dig træt, svag eller have problemer med at koncentrere dig. Hvis du oplever dette eller du 
har andre bivirkninger, skal du ikke føre motorkøretøj eller betjene værktøj eller maskiner. </p>
<p>Onureg indeholder lactose<br />
Onureg indeholder lactose. Kontakt lægen, før du tager dette lægemiddel, hvis lægen har fortalt dig, at 
du ikke tåler visse sukkerarter. </p>
<p>Onureg indeholder natrium<br />
Dette lægemiddel indeholder mindre end 1 mmol (23 mg) natrium pr. tablet, dvs. det er i det 
væsentlige natriumfrit. </p>         </div>"""   
                    
* section[=].section[+]
  * title =  "3. How to take onureg"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "3. How to take onureg"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Tag altid lægemidlet nøjagtigt efter lægens anvisning. Er du i tvivl, så spørg lægen. </p>
<p>Så meget skal du tage </p>
<ul>
<li>
<p>Den anbefalede dosis er 300 mg taget gennem munden én gang dagligt. </p>
</li>
<li>
<p>Din læge kan nedsætte din dosis til 200 mg én gang dagligt. </p>
</li>
</ul>
<p>Onureg gives i behandlingscyklusser af 28 dage. </p>
<ul>
<li>
<p>Du skal tage Onureg hver dag i de første 14 dage af hver cyklus af 28 dage. </p>
</li>
<li>
<p>Dette er efterfulgt af en behandlingsfri periode på 14 dage i resten af cyklussen. </p>
</li>
</ul>
<p>Din læge vil fortælle dig hvilken dosis af Onureg du skal tage. Lægen kan beslutte at: </p>
<ul>
<li>
<p>forlænge din behandling ud over 14 dage i hver behandlingscyklus </p>
</li>
<li>
<p>nedsætte din dosis eller midlertidigt stoppe din behandling </p>
</li>
<li>
<p>nedsætte din behandling til 7 dage. 
Tag altid Onureg nøjagtigt efter lægens anvisning.  </p>
</li>
</ul>
<p>Din læge vil give dig et lægemiddel, der hjælper mod kvalme (føler dig syg) og opkastning. Du skal 
tage det 30 minutter før hver Onureg-tablet og under din første og anden behandlingscyklus. Din læge 
vil bede dig om at tage det i en længere periode, hvis du behøver det. </p>
<p>Sådan tager du medicinen </p>
<ul>
<li>
<p>Tag Onureg én gang dagligt - på det samme tidspunkt hver dag. </p>
</li>
<li>
<p>Synk tabletterne hele med et fuldt glas vand. </p>
</li>
<li>
<p>For at være sikker på, at du får den rette dosis, må du ikke dele, knuse, opløse eller tygge 
tabletterne. </p>
</li>
<li>
<p>Du kan tage lægemidlet med mad eller mellem måltider. 
Hvis du kaster op efter at have taget en tablet, skal du ikke tage en ny dosis på den samme dag. Vent i 
stedet til den næste dag og tag da den næste planlagte dosis. Tag ikke to doser på den samme dag. </p>
</li>
</ul>
<p>Hvis pulver fra en ødelagt tablet kommer i kontakt med din hud, skal du straks vaske huden grundigt 
med sæbe og vand. Hvis pulveret kommer i kontakt med dine øjne, næse eller mund, skal du skylle 
området grundigt med vand. </p>
<p>Hvis du har taget for meget Onureg 
Kontakt straks lægen eller tag på hospitalet, hvis du har taget for mange tabletter end du skulle. Hvis 
det er muligt, tag lægemiddelpakningen og denne indlægsseddel med dig. </p>
<p>Hvis du har glemt at tage Onureg 
Hvis du har glemt at tage Onureg til det sædvanlige tidspunkt, skal du tage din sædvanlige dosis så 
snart du kommer i tanke om det på samme dag og tag din næste dosis til sædvanlig tid den 
efterfølgende dag. Du må ikke tage en dobbeltdosis som erstatning for den glemte eller opkastede 
tablet. </p>
<p>Hvis du holder op med at tage Onureg 
Du må ikke holde op med at tage Onureg, medmindre din læge fortæller dig, at du skal holde op. </p>
<p>Spørg lægen, hvis der er andet som du er i tvivl om. </p>         </div>"""         

        
* section[=].section[+]
  * title = "4. Possible side effects"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "4. Possible side effects"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Dette lægemiddel kan som alle andre lægemidler give bivirkninger, men ikke alle får bivirkninger. </p>
<p>Alvorlige bivirkninger 
Fortæl det straks til lægen, apotekspersonalet eller sygeplejersken, hvis du bemærker en eller flere 
af følgende bivirkninger under behandling med Onureg: </p>
<ul>
<li>
<p>blå mærker eller blødning - dette kan skyldes et lavt antal blodlegemer kaldet "blodplader". </p>
</li>
<li>
<p>feber - dette kan skyldes en infektion, som følge af at have et lavt niveau af hvide 
blodlegemer - hvilket kan være livstruende. </p>
</li>
<li>
<p>diarré, opkastning eller kvalme (føler dig syg). </p>
</li>
</ul>
<p>Andre bivirkninger inkluderer: </p>
<p>Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 patienter): </p>
<ul>
<li>
<p>forstoppelse </p>
</li>
<li>
<p>smerte i maven </p>
</li>
<li>
<p>betændelse (infektioner) i næsen, bihulerne og halsen </p>
</li>
<li>
<p>lungebetændelse </p>
</li>
<li>
<p>træthed eller svaghed </p>
</li>
<li>
<p>appetitløshed </p>
</li>
<li>
<p>smerte forskellige steder i kroppen - dette kan variere fra en skarp smerte til en svag smerte </p>
</li>
<li>
<p>stive led </p>
</li>
<li>
<p>rygsmerter. </p>
</li>
</ul>
<p>Almindelige bivirkninger (kan forekomme hos op til 1 ud af 10 patienter): </p>
<ul>
<li>
<p>influenza </p>
</li>
<li>
<p>urinvejsinfektion (betændelse i urinvejene) </p>
</li>
<li>
<p>høfeber </p>
</li>
<li>
<p>angst </p>
</li>
<li>
<p>vægttab. </p>
</li>
</ul>
<p>Indberetning af bivirkninger 
Hvis du oplever bivirkninger, bør du tale med din læge. Dette gælder også mulige bivirkninger, som 
ikke er medtaget i denne indlægsseddel. Du kan også indberette bivirkninger direkte til 
Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V.  </p>
<p>Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden 
af dette lægemiddel. </p>         </div>"""      
        
* section[=].section[+]
  * title = "5. How to store onureg"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "5. How to store onureg"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Opbevar lægemidlet utilgængeligt for børn. </p>
<p>Tag ikke lægemidlet efter den udløbsdato, der står på blisteren og kartonen efter EXP. Udløbsdatoen 
er den sidste dag i den nævnte måned. </p>
<p>Dette lægemiddel kræver ingen særlige opbevaringsbetingelser. </p>
<p>Spørg apotekspersonalet, hvordan du skal bortskaffe medicinrester. Af hensyn til miljøet må du ikke 
smide medicinrester i afløbet eller skraldespanden. </p>         </div>"""      
        
        
* section[=].section[+]
  * title = "6. Contents of the pack and other information"
  * code = https://spor.ema.europa.eu/rmswi/#100000155538
  * code.text = "6. Contents of the pack and other information"
  * text.status = #additional
  * text.div = """<div xmlns='http://www.w3.org/1999/xhtml'>  <p>Onureg indeholder </p>
<ul>
<li>
<p>Aktivt stof: azacitidin. Hver tablet indeholder enten 200 mg eller 300 mg azacitidin </p>
</li>
<li>
<p>Øvrige indholdsstoffer: croscarmellosenatrium (E468), magnesiumstearat (E572), mannitol 
(E421) og silicificeret mikrokrystallinsk cellulose (E460, E551) </p>
</li>
<li>
<p>200 mg tabletovertræk - Opadry II lyserød indeholder: hypromellose (E464), titandioxid 
(E171), lactosemonohydrat, polyethylenglycol/macrogoler (E1521), triacetin (E1518) og 
jernoxid, rød (E172). Se pkt. 2 “Onureg indeholder sodium". </p>
</li>
<li>
<p>300 mg tabletovertræk - Opadry II brun indeholder: hypromellose (E464), titandioxid (E171), 
lactosemonohydrat, polyethylenglycol/macrogoler (E1521), triacetin (E1518), jernoxid, rød 
(E172), jernoxid, gul (E172) og jernoxid, sort (E172). Se pkt. 2. Udseende og pakningsstørrelser 
Onureg 200 mg filmovertrukne tabletter er lyserød, ovalformede, præget med "200" på den ene side 
og "ONU" på den anden side. </p>
</li>
</ul>
<p>Onureg 300 mg filmovertrukne tabletter er brune, ovalformede, præget med "300" på den ene side og 
"ONU" på den anden side. </p>
<p>De filmovertrukne tabletter er pakket i aluminiumsfolieblister. </p>
<p>Hver pakning indeholder enten 7 eller 14 filmovertrukne tabletter. Ikke alle pakningsstørrelser er 
nødvendigvis markedsført. </p>
<p>Indehaver af markedsføringstilladelsen 
Bristol-Myers Squibb Pharma EEIG 
Plaza Blanchardstown Corporate Park 2 
Dublin 15, D15 TIrland </p>
<p>Fremstiller 
Celgene Distribution B.V. 
Orteliuslaan 13528 BD Utrecht 
Holland </p>
<p>Denne indlægsseddel blev senest ændret  </p>
<p>Andre informationskilder </p>
<p>Du kan finde yderligere oplysninger om dette lægemiddel på Det Europæiske Lægemiddelagenturs 
hjemmeside: http://www.ema.europa.eu. </p>         </div>"""      





                    
Instance: bundlepackageleaflet-en-6b7b5522c872887b5587c6d7e9f380f6
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for onureg Package Leaflet for language en"
Description: "ePI document Bundle for onureg Package Leaflet for language en"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #en

// Composition
* entry[0].fullUrl = "Composition/composition-en-6b7b5522c872887b5587c6d7e9f380f6"
* entry[0].resource = composition-en-6b7b5522c872887b5587c6d7e9f380f6

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp6b7b5522c872887b5587c6d7e9f380f6"
* entry[=].resource = mp6b7b5522c872887b5587c6d7e9f380f6
                            
                    
Instance: bundlepackageleaflet-da-6b7b5522c872887b5587c6d7e9f380f6
InstanceOf: BundleUvEpi
Title: "ePI document Bundle for onureg Package Leaflet for language da"
Description: "ePI document Bundle for onureg Package Leaflet for language da"
Usage: #example


* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* type = #document
* timestamp = "2023-06-27T10:09:22Z"
* language = #da

// Composition
* entry[0].fullUrl = "Composition/composition-da-6b7b5522c872887b5587c6d7e9f380f6"
* entry[0].resource = composition-da-6b7b5522c872887b5587c6d7e9f380f6

// MPD
* entry[+].fullUrl = "MedicinalProductDefinition/mp6b7b5522c872887b5587c6d7e9f380f6"
* entry[=].resource = mp6b7b5522c872887b5587c6d7e9f380f6
                            
                    



Instance: mp6b7b5522c872887b5587c6d7e9f380f6
InstanceOf: MedicinalProductDefinitionUvEpi
Title: "Medicinal Product Onureg 200 mg film-coated tablets"
Description: "Onureg 200 mg film-coated tablets"
Usage: #inline

 
* identifier[+].system = "http://ema.europa.eu/identifier"
* identifier[=].value = "Onureg 200 mg film-coated tablets"
* type = http://hl7.org/fhir/medicinal-product-type#MedicinalProduct "Medicinal Product"

* domain = http://hl7.org/fhir/medicinal-product-domain#Human "Human use"

* status = http://hl7.org/fhir/publication-status#active "active"



* legalStatusOfSupply = $spor-rms#100000072084 "Medicinal product subject to medical prescription"

* name
  * productName = "Onureg 200 mg film-coated tablets"
  * type = $spor-productNamePartType-cs#220000000001 "Full name" 
  
  * part[0]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000002 "Invented name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000003 "Scientific name part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000004 "Strength part"
  
  * part[+]
    * part = "nan"
    * type = $spor-productNamePartType-cs#220000000005 "Pharmaceutical dose form part"
  
  * usage
    * country = urn:iso:std:iso:3166#EU "EU"
    * jurisdiction = urn:iso:std:iso:3166#EU "EU"
    * language = urn:ietf:bcp:47#en  "en"



RuleSet: 6b7b5522c872887b5587c6d7e9f380f6ListRuleset

* identifier.system = "http://ema.europa.eu/identifier" 
* identifier.value = "None"
* identifier[+].system = "http://spor.ema.europa.eu/v2/medicine-name"
* identifier[=].value = "onureg"

* status = #current
* mode = #working

* title = "List of all ePIs associated with onureg"

* subject = Reference(mp6b7b5522c872887b5587c6d7e9f380f6)
* subject.extension[0].url = "http://ema.europa.eu/fhir/extension/medicine-name"
* subject.extension[=].valueCoding = $100000000005#onureg "onureg"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/marketing-authorization-holder"
* subject.extension[=].valueCoding = $100000000005#mah-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/active-substance"
* subject.extension[=].valueCoding = $100000000005#acive-substance-code "None"
* subject.extension[+].url = "http://ema.europa.eu/fhir/extension/domain"
* subject.extension[=].valueCoding = $100000000004#100000000012 "H"

* date = "2015-02-07T13:28:17Z"


* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-en-6b7b5522c872887b5587c6d7e9f380f6) // onureg en
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "en"



* entry
  * flag = urn:oid:1.2.36.1.2001.1001.101.104.16592#01
  * flag.text = "Unchanged"
  * date = "2015-02-07T13:28:17Z"
  * item = Reference(bundlepackageleaflet-da-6b7b5522c872887b5587c6d7e9f380f6) // onureg da
  * item.extension[0].url = "http://ema.europa.eu/fhir/extension/documentType"
  * item.extension[=].valueCoding = $100000155531#100000155538 "B. PACKAGE LEAFLET"
  * item.extension[+].url = "http://ema.europa.eu/fhir/extension/language"
  * item.extension[=].valueCoding = $100000072057#100000072147 "da"




Instance: List-6b7b5522c872887b5587c6d7e9f380f6
InstanceOf: List

* insert 6b7b5522c872887b5587c6d7e9f380f6ListRuleset
    